Janet Clarke - Concepedia

Author

Janet Clarke

Biogen (United States)

Also Known As

Janet B. Clarke, Janet Clarke

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Biogen (United States)Sunesis (United States)Amgen (United States)University of Liverpool Covance (United States)

About

Janet Clarke is an author at Biogen (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	545
2	Immunology	4	4	512
3	Engineering	1	1	33
4	Allergy	1	1	76
5	Pathology	1	1	20

Janet Clarke

Publications

915

Citations

H-Index

Page 1

	Year	Citations
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab Camellia Adams, David E. Allison, Kelly M. Flagella, Cancer Immunology Immunotherapy Recombinant Monoclonal AntibodyMedicineImmunologyAntibody ScreeningBiological Therapy	2005	312
Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation Conor Mallucci, Michael D. Jenkinson, Elizabeth J. Conroy, The Lancet	2019	153
The mechanism of bioactivation and antigen formation of amodiaquine in the rat Anthony Harrison, Neil R. Kitteringham, Janet Clarke, Biochemical Pharmacology MedicineImmunologyAntigen FormationPharmacologyOxidative Stress	1992	104
Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody Janet Clarke, Will Leach, Susanne Pippig, Regulatory Toxicology and Pharmacology ImmunohematologyImmunocytochemical TechniqueAllergyImmunologyImmunodominance	2004	76
Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor Nancy Wehner, George M. Shopp, Ingrid Osterburg, Birth Defects Research Part B Developmental and Reproductive Toxicology	2009	58
Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor Nancy Wehner, George M. Shopp, Satoru Oneda, Birth Defects Research Part B Developmental and Reproductive Toxicology	2009	53
Effects of natalizumab, an α4 integrin inhibitor, on the development of Hartley guinea pigs Nancy Wehner, George M. Shopp, Meredith S. Rocca, Birth Defects Research Part B Developmental and Reproductive Toxicology	2009	40
Effects of natalizumab, an α4 integrin inhibitor, on fertility in male and female guinea pigs Nancy Wehner, Michael J. Skov, George M. Shopp, Birth Defects Research Part B Developmental and Reproductive Toxicology	2009	37
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials Fiona Sewell, Kathryn Chapman, Paul Baldrick, Regulatory Toxicology and Pharmacology EngineeringRecovery AnimalsSafety ScienceSafety Assessment StudiesLaboratory Animal Study	2014	33
In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon β-1a Xiao Hu, Kenneth N. Olivier, Evelyne Polack, Journal of Pharmacology and Experimental Therapeutics	2011	29

Page 1